Mavacamten Drug Asset Due Diligence Report 2026

This Mavacamten Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Mavacamten can convert its Small molecule drug profile and Cardiac myosin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Mavacamten (query alias: mavacamten)
Modality / target	Small molecule drug; Cardiac myosin; Cardiac myosin inhibitors
Highest global status	Approved
Originator	Bristol Myers Squibb Co.
Active developers	Bristol-Myers Squibb Pharma EEIG, Bristol Myers Squibb Co., Bristol-Myers Squibb Australia Pty Ltd.

The MCP disease footprint includes Hypertrophic obstructive cardiomyopathy, Hypertrophic Cardiomyopathy without Obstruction, Cardiomyopathy, Hypertrophic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07557498	Not Applicable	Recruiting	362	Participant blood pressure (both systolic and diastolic)
NCT07529938	Not Applicable	Completed	222	Change in Resting Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30
JPRN-jRCT1041260015	Not Applicable	募集中	45	Difference (change value) between peak VO2 measured during baseline cardiopulmonary exercise testing while taking sibenzoline and peak VO2 measured 40 weeks after switching to oral administration of mabacamten.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study

Phase 2; n=79; evaluation: Positive. Reported fields: KCCQ-23 CSS = 7.1 point ; KCCQ-23 CSS = 5.7 point ; KCCQ-23 CSS = 7.3 point

Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

Phase 3; n=44; evaluation: Positive. Reported fields: LVOT-G = The trial met its primary endpoint, demonstrating a statistically significant reduction from baseline in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 versus placebo, indicating Camzyos was effective in improving LVOT obstruction. Met; LVOT-G = The trial met its primary endpoint, demonstrating a statistically significant reduction from baseline in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 versus placebo, indicating Camzyos was effective in improving LVOT obstruction. Met

Effects of Mavacamten on Cardiac Magnetic Resonance Features in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy

Phase 3; n=81; evaluation: Positive. Reported fields: LV mass index = -30.8 g/m^2 ( -41.5 to -20.1)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Mavacamten addresses Hypertrophic obstructive cardiomyopathy, Hypertrophic Cardiomyopathy without Obstruction, Cardiomyopathy, Hypertrophic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-10-24	BMS obtained LianBio’s exclusive rights to mavacamten,in conjunction with termination of the exclusive license agreement LianBio previously entered into with MyoKardia.	Phase 3	US$40.0M upfront; US$147.5M milestones; US$187.5M stated total
2020-10-05	Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise	Phase 2	US$13,100.0M stated total
2019-01-02	MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Amorphous solid dispersion of mavacamten”. The milestone feed surfaced a patent-application signal described as “Process for preparing mavacamten and process intermediate”. The milestone feed surfaced a patent-application signal described as “Process for the preparation of mavacamten”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO